Global Penicillin Drug Market is segmented By Source (Natural, Air-driven turbines, Semi synthesis), By Class (Aminopenicillin, Antipseudomonal Penicillin, Beta-lactamase Inhibitor, Penicillinase-resistant Penicillin), By Route of Administration (Oral, Parenteral), By Region (North America, Europe, South America, Asia-Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
Penicillin Drug Market is predicted to reach a CAGR 4.4% during the forecast period (2024-2031).
In the penicillin group of drugs Penicillin V is an antibiotic. It fights bacteria in the body. It is used to treat different infections caused by bacteria, such as ear infections.
Market Summary
|
Metrics |
Details |
|
Market CAGR |
4.4% |
|
Segments Covered |
By Source, By Class, By Route of Administration, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For more details on this report - Request for Sample
Market Dynamics
The rising prevalence of bacterial infection and demand for effective and newer antibiotics will drive the penicillin drug market in the forecast period.
The rising prevalence of bacterial infection will drive the penicillin drug market
Bacterial infections show a large impact on public health. The disease can occur in anybody and can be caused by the organism itself or by the response of the body to its presence. Bacteria are transmitted to humans through water, food, air, or living vectors. The modes of transmission of bacterial infection are contact, airborne, droplet, vectors, and vehicular. Respiratory infections were the most common (45.5%), followed by blood (23.3%) and urinary (16.1%). Gram-negative bacteria were common Acinetobacter baumannii (20.9%), Klebsiella pneumoniae (19.7%), Escherichia coli (18.3%), and Pseudomonas aeruginosa (14.0%). There is resistance with high prevalence to common antibiotics. The global prevalence of multidrug-resistant (MDR) bacteria was 34% (95% confidence interval 31%-37%).
Penicillin is administered to patients with an infection caused by bacteria. According to the National Library of Medicine, a few types of bacterial infections that can be treated with penicillin include gonorrhea, pneumonia, meningitis, syphilis and strep throat. It may be used to prevent dental infections. As an antibiotic, penicillin kills bacteria or prevents them from growing and multiplying. The drug works by attacking enzymes that build the cell walls of bacteria. Different kinds of penicillin are used for various infections. Some types of penicillin are amoxicillin, ampicillin, Augmentin, penicillin G and penicillin V.
The rising demand for effective and newer antibiotics will drive the penicillin drug market in the forecast period
The Discovery and launch of new antibiotics to market is a formidable challenge but it needs to be addressed if we want to be better protected against the growing threat of drug-resistant infections. The discovery of penicillin the first antibiotic has revolutionized modern medicine. Antibiotics have become a common class of drugs used to treat and prevent infections and are used in complex surgeries from cesarean sections to hip replacement surgeries and organ transplants. But they are not as effective as they used to be. Over time certain bacteria, so-called ‘superbugs,’ have learned and adapted to resist the effects of the drugs designed to kill them. The collective overuse of antibiotics in animals, humans and plants has accelerated this process. In recent times, infections due to drug-resistant have become a serious threat to people’s health. Every year many lives are lost because of infections that cannot be treated with existing drugs. To save modern medicine discovery of new antibiotics able to kill drug-resistant bacteria is essential.
Over time, bacteria will learn to resist the new drugs. To stay ahead in this constant race against superbugs, we also need innovations in developing diagnostics, vaccines and better prevention control and surveillance. According to the WHO and the Pew Charitable Trust, there are currently between 40 and 50 antibiotics in clinical development.
The rising number of multi-drug resistant (MDR) pathogens will hamper the penicillin drug market
Representing a serious problem for public health antibiotic resistance is one of the greatest challenges in the health system. Initially, these strains were restricted to the hospital environment, but now they are found everywhere. Globalization, aquaculture, use of multiple broad-spectrum agents, excessive use of antibiotics in animal husbandry and lack of good antimicrobial stewardship are listed as the factors responsible for the spread of antibiotic resistance. The increase in the rate of antibiotic-resistant pathogens implies having fewer antimicrobial agents to treat infections.
Huge amounts of antibiotics used for human therapy, farm animals and even fish in aquaculture is used in the selection of pathogenic bacteria resistant to multiple drugs. In bacteria, multidrug resistance is generated by one of two mechanisms. Initially, these bacteria accumulate multiple genes, each coding for resistance to a single drug within a single cell. This accumulation occurs typically on-resistance (R) plasmids. Second, multidrug resistance occurs by the increased expression of genes that code for multidrug efflux pumps, extruding a wide range of drugs. Multidrug resistance in bacteria occurs by the accumulation of genes on-resistance (R) plasmids or transposons, with each code for resistance to a specific agent, and by the multidrug efflux pumps action, each of which pumps out more than one drug type.
COVID-19 Impact Analysis
The healthcare industry has been affected by COVID-19. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has seen to affect the penicillin drug market as many have stopped manufacturing units.
Market Segment Analysis
The natural penicillin segment will dominate the market
The two so-called natural penicillins are both produced biosynthetically from Penicillium chrysogenum by fermentation. Benzylpenicillin (penicillin G) is formed if phenylacetic acid is added to the culture medium, and Phenoxymethylpenicillin (penicillin V) is formed when phenoxyacetic acid is added. The first antibiotics natural Penicillins were used in clinical practice. They are based on the penicillin- G structure and inhibit bacterial cell wall synthesis and are generally bactericidal. Natural penicillins are effective against gram-positive bacteria such as staphylococci, streptococci and gram-negative bacteria such as meningococci, Treponema, Borrelia and Leptospira.
They include penicillin G for parenteral use and penicillin V for oral use only. These drugs primarily indicate infections caused by gram-positive organisms, including anaerobes (except Bacteroides fragilis). Spirochetes and some gram-negative organisms are susceptible. However, others require higher concentrations. The Pseudomonas aeruginosa and Enterobacteriaceae are resistant. Penicillin V should not be used for serious infections due its variable and incomplete absorption.
Aminopenicillin class will dominate the penicillin drug market
The aminopenicillin class of semisynthetic penicillins contains an amino substitution in the phenyl acetamido side chain of the penam nucleus, providing a polar charge on the molecule that allows activity against gram-negative pathogens, including Escherichia coli and Haemophilus influenzae. However, aminopenicillins are not stable to staphylococcal penicillinases or the hundreds of different β-lactamases elaborated by gram-negative pathogens. Their activity against other gram-positive organisms, such as group A and group B Streptococcus spp., is excellent, and activity against most enterococci is equivalent to or better than penicillin G.
Aminopenicillins are a group of antibiotics belonging to the penicillin family with an additional amino group that enhances its antibacterial activity. They are used for a range of wide infections such as urinary, respiratory, skin, and gastrointestinal infections. Aminopenicillins are indicated to treat upper respiratory tract infections, lower respiratory tract infections, bacterial gastroenteritis (ampicillin only), meningitis, bacterial endocarditis and urinary tract infections caused by susceptible (i.e., non–β-lactamase–producing) organisms.
The oral segment will dominate the penicillin drug market
Penicillins (except bacampicillin tablets, penicillin V, amoxicillin, pivmecillinam and pivampicillin) are best taken with a glass full (8 ounces) of water on an empty stomach (either 1 hour before or 2 hours after meals) unless directed by the doctor. Pivmecillinam, penicillin V, pivampicillin and amoxicillin may be taken on a full or empty stomach.
Amoxicillin in liquid form may be taken by itself or mixed with different formulas or other cold drinks. If mixed with other liquids, it is to be taken immediately after mixing. One should be sure to drink all the liquid to get the full dose of medicine. The liquid form of this medicine is best to be taken with a full glass of water on an empty stomach unless otherwise directed by the doctor. The tablet form of the medicine can be taken on an empty or full stomach. An oral tablet of Penicillin V is used to treat certain infections caused by bacteria. It won't treat infections caused by viruses. This drug's bacterial infections include streptococcal upper respiratory tract infections, scarlet fever, and erysipelas infections.
Market Geographical Share
North America region will dominate the penicillin drug market
The increasing prevalence of bacterial infections and major key players will dominate the penicillin drug market. In the U.S., according to the report, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35,000 people die as a result. The U.S. FDA approved Recarbrio (a combination of relebactam and imipenem-cilastatin) to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older. Recarbrio was previously FDA-approved to treat patients with complicated urinary tract infections and intra-abdominal infections with limited or no alternative treatment options.
Penicillin is a prescription medication and should not be used casually. Due to this, penicillin OTC (over the counter) is not available, and one cannot just buy penicillin online in the United States.
Penicillin Drug Market Competitive Landscape
Major key players in the penicillin drug market are Pfizer, Inc., Novartis AG, Sanofi S.A., Astellas Pharma, Inc., GlaxoSmithKline plc, Merck Co. and Inc., Fujifilm Toyama Chemical Co. Ltd., Sun Pharmaceutical Industries, Lupin Limited, Cipla Limited, Bayer AG, F. Hoffmann-La Roche AG, Daiichi Sankyo Company Ltd., Qpex Biopharma, Shanghai Hegno Pharmaceutical Holding Co., Ltd., Jiangxi Tianxin Pharmaceutical Co. Ltd. and Nanjing Pharmaceutical Factory Co. Ltd.
Key Companies to Watch
Qpex Biopharma
Overview: A resistance-focused infectious disease company, Qpex Biopharma, Inc. is on a mission to make both a sustainable and dramatic improvement in inpatient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, they create novel products and development strategies that overcome multi-drug resistance. They are advancing a robust portfolio of treatments that will bring innovation to antibiotic development and deliver the right treatments to patients in the right settings.
Product Portfolio: The company comprises drug discovery, anti-infective therapies, antibiotics, drug development, drug resistance, microbiology, and boron chemistry.
Key Development: Qpex Biopharma, Inc., a resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, has announced the initiation of a Phase 1 study of QPX9003, a next-generation intravenous (IV)-administered synthetic polymyxin for infections caused by gram-negative drug-resistant pathogens.
The penicillin drug market report would provide access to an approx. 60 market data table, 50 figures and 180 pages.
